| Name | Title | Contact Details |
|---|---|---|
Paul Butler |
Chief Information Officer | Profile |
Maryland Health Benefit Exchange’s (MHBE) resource site for stakeholders. We continue to work toward the opening of the marketplace in October 2013 of Maryland Health Connection, the state-based health insurance exchange where Maryland residents and small businesses will be able to explore and compare health insurance plans, qualify for cost-sharing reductions and tax credits and complete the enrollment process. The information available through this site supports our work with stakeholders. Meeting schedules and materials, career information, and procurement details are routinely posted. Additionally, the site serves as a resource for the many advisory committees and programs in progress and in development as we collectively work together to establish a health insurance marketplace that best meets the needs of all Marylanders.
MedCare and its affiliated entities manage approximately $1 billion in assets, the substantial majority of which are related to the medical and healthcare services industry.
Freedom Health, Inc. is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Xoft Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Sunnyvale, CA. To find more information about Xoft Inc, please visit www.xoftinc.com
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic